CVRx to Present at the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

CVRx, a medical device company focused on neuromodulation solutions for cardiovascular diseases, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 3:45 pm Pacific Time. The presentation will be available via a live audio webcast, with a replay accessible for 30 days. CVRx's flagship product, Barostim, is an FDA-approved device designed to reduce heart failure symptoms by improving autonomic nervous system balance through electrical pulses to baroreceptors in the carotid artery. For more details, visit ir.cvrx.com.

MINNEAPOLIS, Dec. 28, 2022 (GLOBE NEWSWIRE) --  CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will participate in the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023. The Company is scheduled to present at the conference at 3:45 pm Pacific Time.

A live audio webcast of the conference presentation will be available online here, and at the investor relations page of the Company’s website at ir.cvrx.com. A replay of the webcast will be archived on the website for approximately 30 days.

About CVRx, Inc.

CVRx is focused on the development and commercialization of Barostim™, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body’s baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:

Mark Klausner or Mike Vallie

ICR Westwicke

443-213-0501

ir@cvrx.com

Media Contact:

Erich Sandoval

Finn Partners

212-867-1762

erich.sandoval@finnpartners.com

FAQ

What date will CVRx present at the J.P. Morgan Healthcare Conference?

CVRx will present on January 11, 2023.

What time is CVRx's presentation at the J.P. Morgan Healthcare Conference?

The presentation is scheduled for 3:45 pm Pacific Time.

Where can I watch the CVRx conference presentation?

The presentation will be available via a live audio webcast on the company's investor relations page.

What is Barostim and how does it work?

Barostim is a medical device that uses neuromodulation to alleviate heart failure symptoms by delivering electrical pulses to baroreceptors.

Has Barostim received FDA approval?

Yes, Barostim is FDA-approved and also has received the CE Mark for use in Europe.